Product News: ASI and Olympus Announce Distribution Agreement for Microscopy Imaging Solutions

29 May 2012

Applied Spectral Imaging (ASI) Ltd. and OLYMPUS Europa Holding GmbH have announced the signing of a European framework agreement, outlining the terms for distribution by Olympus subsidiaries in Europe of the GenASIs automated imaging platforms for genetic and pathological analysis.

The agreement underlines both companies’ intent to establish cooperation with individual Olympus distributors in Europe. These agreements will be based on the Framework Agreement to deliver integrated computer aided microscopy imaging and analysis for cytogenetics and pathology.

The GenASIs advanced cytogenetic and pathology platforms are the foundation of ASI’s offering. With its superior imaging and analysis capabilities, ASI provides state-of-the-art diagnostic aids, offering cytogeneticists and pathologists accurate biomedical analysis. GenASIs enables automated pathology tissue analysis for primary diagnostics, creating reproducible and reliable results. The GenASIs platforms offer a comprehensive solution ensuring reliability and quality results every time, while allowing cytogeneticists, pathologists and technologists to focus on the clinical rather than the technical components.

ASI’s advanced solutions integrated with Olympus’ microscopy solutions accommodate the market demand for faster, more powerful imaging and analysis tools. This unparalleled synergy caters to the growing market need for high throughput solutions empowering laboratories to do more with less.

GenASIs will complement Olympus’ solutions by offering an integrated imaging, digital image capture and biomedical analysis platform. GenASIs is FDA cleared for FISH clinical applications such as UroVysion, HER2/neu, CEP XY and Karyotyping.

“We are excited about our cooperation with Olympus. Cooperating with the world’s leader in microscopy will further enhance ASI’s position as the leaders in computer aided biomedical microscopy imaging and analysis” said Limor Shiposh, CEO of Applied Spectral Imaging.

With this co-operation agreement both companies show their commitment of working together in order to offer more competitive integrated solutions and to facilitate the daily work in medical applications.